ANNEXON INC. - COMMON STOCK

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Jan 2026 17:05:12 By Nasdaq GlobeNewswire

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

12 Jan 2026 07:00:01 By Nasdaq GlobeNewswire

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

08 Jan 2026 08:00:01 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

07 Jan 2026 16:05:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

16 Dec 2025 19:31:15 By Nasdaq GlobeNewswire

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

14 Nov 2025 16:01:00 By Nasdaq GlobeNewswire

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

12 Nov 2025 22:55:39 By Nasdaq GlobeNewswire

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 Nov 2025 16:12:38 By Nasdaq GlobeNewswire

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

10 Nov 2025 16:05:01 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in Upcoming September Investor Conferences

27 Aug 2025 08:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

18 Aug 2025 16:05:00 By Nasdaq GlobeNewswire

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

14 Aug 2025 16:05:01 By Nasdaq GlobeNewswire

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

07 Aug 2025 16:30:00 By Nasdaq GlobeNewswire

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

24 Jul 2025 07:00:00 By Nasdaq GlobeNewswire

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

18 Jun 2025 16:05:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

29 May 2025 16:05:00 By Nasdaq GlobeNewswire

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

19 May 2025 16:05:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 May 2025 16:05:46 By Nasdaq GlobeNewswire

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

12 May 2025 08:00:00 By Nasdaq GlobeNewswire

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

09 May 2025 17:00:00 By Nasdaq GlobeNewswire